MAY 12, 2020 8:43 PM PDT

Novel Drug Approved for Non-Small Cell Lung Cancer

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung cancer (NSCLC). The therapeutic called ‘Tabrecta™ (capmatinib, formerly INC280)’ is an oral MET inhibitor for patients with a METex14 mutation in their tumors.

Learn more about non-small cell lung cancer (NSCLC):

 

 

“Non-small cell lung cancer is a complex disease, with many different possible mutations that may encourage the cancer’s growth,” said Juergen Wolf, MD, from the Center for Integrated Oncology, University Hospital Cologne and lead investigator of the GEOMETRY study. “MET exon 14 skipping is a known oncogenic driver. With today’s decision by the FDA, we can now test for and treat this challenging form of lung cancer with targeted therapy, offering new hope for patients with NSCLC harboring this type of mutation.”

The approval of Trabecta is based on findings from the pivotal GEOMETRY mono-1 Phase II clinical trial. The most common side-effects noted were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

“Today, and especially during these difficult times, we are incredibly proud that Tabrecta is the first treatment approved by the FDA specifically to treat patients diagnosed with this aggressive NSCLC associated with METex14,” said Susanne Schaffert, PhD, President, Novartis Oncology. “In our quest to reimagine medicine, we have worked tirelessly over the past decades to advance the understanding and treatment of NSCLC, striving to make a difference in patients’ lives, one mutation at a time. We thank all the physicians, patients and families involved in the Tabrecta clinical trials, and we remain committed to advancing innovative solutions for the patients we work to serve.”

Source: Novartis

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 20, 2020
Cancer
Fighting Cancer with Black Pepper
JUL 20, 2020
Fighting Cancer with Black Pepper
In the never-ending search for the next treatment or cure, many researchers turn towards nature. The study of black pepp ...
JUL 23, 2020
Cardiology
Protecting the Heart After a Heart Attack
JUL 23, 2020
Protecting the Heart After a Heart Attack
Cardiovascular disease accounts for thirty percent of mortalities around the world. These diseases start small and slowl ...
AUG 04, 2020
Cannabis Sciences
Nanotechnology Makes Medicinal Cannabis More Effective
AUG 04, 2020
Nanotechnology Makes Medicinal Cannabis More Effective
It seems that cannabis can treat everything- from chronic pain to acne and maybe even cancer. But as cannabinoids are kn ...
AUG 11, 2020
Drug Discovery & Development
Scientists Discover Key Gene Behind Antibiotic Resistance
AUG 11, 2020
Scientists Discover Key Gene Behind Antibiotic Resistance
Scientists from Oxford University have shown that a single gene can make some strains of Staphylococcus aureus (the bact ...
SEP 07, 2020
Microbiology
How THC Can Help Relieve a Respiratory Disorder
SEP 07, 2020
How THC Can Help Relieve a Respiratory Disorder
Acute respiratory distress syndrome (ARDS) occurs when fluid builds up in the sacs in the lungs that hold air, and the l ...
SEP 10, 2020
Drug Discovery & Development
Common Painkiller Increases Risk-Taking Behavior
SEP 10, 2020
Common Painkiller Increases Risk-Taking Behavior
Researchers from Ohio State University have found that the common painkiller, paracetamol ( also known as Tylenol and Pa ...
Loading Comments...